Streetbeat News

ABVX

Abivax SA American Depositary Shares

https://www.abivax.com

Industry

Biotechnology

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Open

8.80

Mkt cap

551M

Volume

76K

High

8.80

P/E Ratio

-2.39

52-wk high

17.02

Low

8.51

Div yield

N/A

52-wk low

8.51

Abivax, a clinical-stage biotechnology company, released its key financial information for Q3 2024. The company is focused on developing therapeutics for chronic inflammatory diseases.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

Abivax has enrolled the first patient in its Phase 2b trial, ENHANCE-CD, for the drug Obefazimod, aimed at treating Crohn's Disease.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 8:01 pm

Abivax has reported positive interim results for its drug Obefazimod, showing efficacy and safety in treating moderate to severe ulcerative colitis over a two-year period. The drug maintained clinical remission and was well-tolerated with no new safety concerns.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 7:08 am

Abivax SA will present new data on its lead drug candidate, obefazimod, at the UEG Week 2024, highlighting its potential in treating ulcerative colitis. The presentation will focus on Phase 2b trial data, suggesting obefazimod as a promising once-daily oral therapy.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 6:38 am

Abivax announced promising preclinical results for its combination therapy of obefazimod and etrasimod in treating inflammatory bowel disease. The study showed significant improvements in disease markers, suggesting potential for future development.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 8:04 pm

The Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) has surpassed the 600-patient enrollment milestone and is on track to reach full enrollment by early Q1 2025. Baseline participant characteristics and trial trends are consistent with observations from the Phase 2b trial.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 6:46 am

Laidlaw & Co. has initiated coverage on Abivax (NASDAQ:ABVX) with a Buy rating and set a price target of $48.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 12:05 pm

Abivax SA (NASDAQ: ABVX) provided an update on its Phase 3 ABTECT trial for obefazimod in ulcerative colitis, which is on track to complete enrollment in early Q1 2025. The company expects top-line results in early Q2 2025 and has sufficient cash to fund operations through Q4 2025. Leadership changes include Sylvie Grégoire as Chair of the Board, Dr. Fabio Cataldi as Chief Medical Officer, and Dr. David Zhang as Chief Strategy Officer.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 8:01 pm

Several major stocks, including AMC Networks, Louisiana-Pacific, and others, are experiencing declines in Monday's pre-market session. AMC Networks fell sharply due to a private offering of convertible senior notes, while Louisiana-Pacific was downgraded by Goldman Sachs.

Portfolio Pulse from Avi Kapoor

June 17, 2024 | 11:41 am

BTIG has initiated coverage on Abivax (NASDAQ:ABVX) with a Buy rating and set a price target of $43.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 11:36 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.